Autres langues Mesoblast Limited Nasdaq

Actions

MESO

US5907174016

Marché Fermé - Nasdaq Autres places de cotation 22:30:00 03/05/2024			Varia. 5j.	Varia. 1 janv.
7,5 ^USD	+2,88%		+20,19%	+240,91%

26/03	La FDA déclare que les données de l'étude de Mesoblast sont suffisantes pour soutenir la soumission d'une BLA	MT
26/03	Mise à jour sectorielle : Les actions du secteur de la santé progressent en fin d'après-midi	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024	30/04
ADRs End Higher; Connect Biopharma Climbs 26%	01/04
ADRs End Lower; NuCana Slides 15%	28/03
Reddit Inc. (NYSE: RDDT) Surges, Uncovering Undervalued Opportunities: DYAI, INBS, MESO, VTAK	28/03
ADRs End Lower; Quhuo Drops 53%	26/03
FDA Says Mesoblast Trial Data Sufficient to Support BLA Submission	26/03
Sector Update: Health Care Stocks Advance Late Afternoon	26/03
Top Midday Gainers	26/03
Sector Update: Health Care Stocks Steady Premarket Tuesday	26/03
Wall Street Set to Open Modestly Higher Tuesday Ahead Consumer Confidence Reading	26/03
Top Premarket Gainers	26/03
Mesoblast Shares Jump After FDA Nod for Submission of Remestemcel-L Application	26/03
Mesoblast to Resubmit Application for Potential Pediatric Treatment of Graft Versus Host Disease; Shares Gain Pre-Bell	26/03
United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)	26/03
United States Food & Drug Administration Notifies Mesoblast Limited of Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease	26/03
Mesoblast Limited(ASX:MSB) added to S&P/ASX Emerging Companies Index	18/03
Mesoblast Raises AU$97 Million From Entitlement Offer, Institutional Placement	14/03
Mesoblast Raises AU$97 Million for Phase Three Registration Trials	14/03
Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer	14/03
Sector Update: Health Care Stocks Softer Late Afternoon	11/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Mesoblast Limited Nasdaq

Actions

MESO

US5907174016

Autres langues

Filtres